Skip to main content

Mylanta AR Disease Interactions

There are 2 disease interactions with Mylanta AR (famotidine).

Major

H2 antagonists (applies to Mylanta AR) GI bleeding

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Hemorrhage

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.

References

  1. (2002) "Product Information. Pepcid (famotidine)." Merck & Co., Inc
  2. (2002) "Product Information. Axid (nizatidine)." Lilly, Eli and Company
  3. (2001) "Product Information. Tagamet (cimetidine)." SmithKline Beecham
  4. (2001) "Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome
  5. (2002) "Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals
View all 5 references
Moderate

Famotidine (applies to Mylanta AR) renal dysfunction

Moderate Potential Hazard, High plausibility.

Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous). The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients. Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients. Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient's clinical response.

References

  1. Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR (1987) "Disposition of famotidine in renal insufficiency." J Clin Pharmacol, 27, p. 782-7
  2. Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H (1988) "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol, 26, p. 315-21
  3. Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T (1988) "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther, 10, p. 656-63
  4. Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. (1985) "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol, 28, p. 327-31
  5. Kroemer H, Klotz U (1987) "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol, 25, p. 458-63
  6. (2002) "Product Information. Pepcid (famotidine)." Merck & Co., Inc
  7. Gladziwa U, Klotz U (1994) "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet, 27, p. 393-408
View all 7 references

Mylanta AR drug interactions

There are 298 drug interactions with Mylanta AR (famotidine).

Mylanta AR alcohol/food interactions

There is 1 alcohol/food interaction with Mylanta AR (famotidine).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer